New HIV Vaccine Candidate Shows Promise in Early Trials, Faces Safety Challenges
For a vaccine to be effective, it must raise antibodies that neutralize intruders and be safe for most people without major side effects. Veuer’s Maria Mercedes Galuppo has the story.
Category
🗞
NewsTranscript
00:00 For a vaccine to be effective, it must raise antibodies that neutralize intruders and be safe for most people without major side effects.
00:08 The research published in Cell reports that a new HIV vaccine candidate is facing these challenges in early-stage clinical trials,
00:16 succeeding in generating antibodies but encountering safety issues.
00:20 The vaccine produced broadly neutralizing antibodies in some participants,
00:24 but the trial was halted after a severe allergic reaction to a stabilizing component, polyethylene glycol.
00:31 Despite the setback, the vaccine showed a strong immune response after two doses,
00:35 and B-naps were generated in two participants, neutralizing 15 to 35% of HIV strains in cell experiments.
00:44 (upbeat music)